The manufacturer hopes the drug will be available globally after 2025. Photo: Xinhua

New Chinese Alzheimer’s drug Oligomnnate goes on sale to patients, despite concerns from some medical professionals

  • Experimental seaweed-based treatment is now approved for sale but doubts remain about how effective it will be
  • It is the first new treatment for disease in 17 years, but regulators have demanded further tests to prove its long-term safety and worth
Topic |   China Society

TOP PICKS

The manufacturer hopes the drug will be available globally after 2025. Photo: Xinhua
READ FULL ARTICLE
Phoebe Zhang

Phoebe Zhang

Phoebe Zhang is a society reporter with the South China Morning Post. She likes to write human-interest stories and has written many about people living on the fringes of society. She believes there's no story or person that's too small.